Your browser is no longer supported. Please, upgrade your browser.
Adverum Biotechnologies, Inc.
Index- P/E- EPS (ttm)-1.28 Insider Own0.30% Shs Outstand88.87M Perf Week18.27%
Market Cap1.43B Forward P/E- EPS next Y-1.39 Insider Trans10.41% Shs Float66.99M Perf Month9.52%
Income-98.80M PEG- EPS next Q-0.32 Inst Own96.40% Short Float15.33% Perf Quarter20.42%
Sales0.00M P/S- EPS this Y15.00% Inst Trans-1.59% Short Ratio10.18 Perf Half Y-17.04%
Book/sh5.23 P/B2.66 EPS next Y-6.10% ROA-28.00% Target Price- Perf Year20.42%
Cash/sh4.43 P/C3.14 EPS next 5Y- ROE-32.20% 52W Range7.36 - 26.98 Perf YTD28.41%
Dividend- P/FCF- EPS past 5Y16.40% ROI-39.20% 52W High-48.41% Beta1.54
Dividend %- Quick Ratio28.50 Sales past 5Y-15.30% Gross Margin- 52W Low89.13% ATR1.01
Employees114 Current Ratio28.50 Sales Q/Q- Oper. Margin- RSI (14)61.68 Volatility7.66% 7.64%
OptionableYes Debt/Eq0.00 EPS Q/Q-25.00% Profit Margin- Rel Volume2.52 Prev Close12.17
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume1.01M Price13.92
Recom2.10 SMA2016.57% SMA509.80% SMA200-6.53% Volume2,466,851 Change14.38%
Dec-16-20Initiated UBS Neutral $13
Nov-12-20Upgrade Raymond James Underperform → Mkt Perform
Jun-26-20Downgrade Raymond James Mkt Perform → Underperform
May-13-20Initiated RBC Capital Mkts Outperform $24
May-05-20Upgrade SunTrust Hold → Buy $13 → $21
Apr-28-20Initiated Goldman Buy $17
Mar-16-20Initiated SVB Leerink Outperform $17
Feb-10-20Upgrade Chardan Capital Markets Neutral → Buy $20
Feb-10-20Upgrade Cantor Fitzgerald Neutral → Overweight $8 → $21
Oct-15-19Reiterated Chardan Capital Markets Neutral $6 → $10
Sep-13-19Reiterated Chardan Capital Markets Neutral $10 → $6
Jun-14-19Resumed Raymond James Mkt Perform
Nov-02-18Downgrade SunTrust Buy → Hold
Nov-02-18Downgrade Raymond James Outperform → Mkt Perform
Sep-21-18Initiated Cantor Fitzgerald Overweight
Aug-30-18Initiated SunTrust Buy $11
Feb-15-18Resumed Piper Jaffray Overweight $12
Oct-12-17Initiated Raymond James Outperform $6
Jan-11-21 12:00PM  
Jan-08-21 08:49AM  
Jan-07-21 11:57AM  
Jan-05-21 09:00AM  
Dec-21-20 10:23AM  
Dec-14-20 09:00AM  
Nov-23-20 11:00AM  
Nov-14-20 10:00AM  
Nov-08-20 07:32AM  
Nov-05-20 06:35PM  
Oct-20-20 09:00AM  
Oct-09-20 08:56AM  
Sep-29-20 05:23PM  
Sep-15-20 08:00AM  
Sep-10-20 08:00AM  
Sep-08-20 08:57AM  
Aug-20-20 07:57AM  
Aug-18-20 09:00AM  
Aug-17-20 08:51AM  
Aug-12-20 09:37PM  
Aug-11-20 04:01PM  
Aug-10-20 05:35PM  
Jul-29-20 04:05PM  
Jul-21-20 08:00AM  
Jul-20-20 11:07AM  
Jul-13-20 08:30AM  
Jul-06-20 09:00AM  
Jun-30-20 11:50PM  
Jun-25-20 04:01PM  
Jun-16-20 08:13AM  
Jun-15-20 04:01PM  
Jun-04-20 04:05PM  
May-29-20 11:30AM  
May-28-20 05:45PM  
May-25-20 11:30AM  
May-21-20 04:05PM  
May-09-20 08:00AM  
May-07-20 11:30AM  
May-06-20 12:53PM  
May-05-20 04:11PM  
May-04-20 05:10PM  
May-03-20 07:00AM  
Apr-30-20 04:05PM  
Apr-28-20 12:00PM  
Apr-27-20 04:01PM  
Apr-20-20 04:05PM  
Apr-01-20 01:42AM  
Mar-26-20 08:55AM  
Mar-18-20 12:00PM  
Mar-16-20 06:06AM  
Mar-12-20 05:55PM  
Mar-11-20 04:38PM  
Mar-05-20 04:01PM  
Mar-04-20 04:25PM  
Mar-03-20 02:20PM  
Mar-02-20 05:50PM  
Feb-26-20 06:50PM  
Feb-25-20 03:00PM  
Feb-24-20 05:31PM  
Feb-19-20 04:01PM  
Feb-17-20 10:06AM  
Feb-15-20 10:09AM  
Feb-14-20 04:01PM  
Feb-11-20 08:27PM  
Feb-10-20 04:01PM  
Feb-08-20 03:06PM  
Feb-02-20 01:04PM  
Jan-31-20 06:40AM  
Jan-28-20 04:02PM  
Jan-27-20 04:00PM  
Jan-12-20 06:00PM  
Jan-07-20 10:00AM  
Dec-18-19 04:01PM  
Dec-14-19 08:41PM  
Dec-02-19 10:53AM  
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, engages in developing gene therapy product candidates to treat ocular and rare diseases. Its pipeline of product candidates includes ADVM-022, an adeno- associated virus (AAV). 7m8-aflibercept for the treatment of wet age-related macular degeneration; ADVM-043, an investigational gene therapy candidate for the treatment of alpha-1 antitrypsin deficiency; and ADVM-053, a preclinical gene therapy product candidate for the treatment of hereditary angioedema. The company has collaboration agreements with Editas Medicine, Inc. to leverage its proprietary AAV vectors for genome editing technologies to treat up to five inherited retinal diseases; and Regeneron Pharmaceuticals, Inc. for the development of up to eight distinct ocular therapeutic targets. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was founded in 2006 and is headquartered in Redwood City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Machado PatrickDirectorJan 15Buy11.5210,000115,17478,182Jan 19 08:33 PM
Fischer LaurentCEO and DirectorJan 15Buy11.538,60099,19116,292Jan 19 08:32 PM
Soparkar PeterChief Legal OfficerAug 17Buy13.007,69299,99610,692Aug 19 06:48 PM
Fischer LaurentCEO and DirectorAug 17Buy13.007,69299,9967,692Aug 19 06:45 PM
Gasmi MehdiDirectorJul 20Option Exercise4.805,00024,000279,442Jul 22 09:44 PM
Gasmi MehdiDirectorJul 20Sale17.605,00087,978274,442Jul 22 09:44 PM
Gasmi MehdiDirectorJun 22Option Exercise4.8023,605113,304298,047Jun 23 06:58 PM
Gasmi MehdiDirectorJun 22Sale25.0623,605591,617274,442Jun 23 06:58 PM
Gasmi MehdiDirectorJun 18Option Exercise4.8011,12753,410285,569Jun 18 09:45 PM
Gasmi MehdiDirectorJun 18Sale25.0111,127278,329274,442Jun 18 09:45 PM
Gasmi MehdiDirectorJun 17Option Exercise4.802681,286274,710Jun 18 09:45 PM
Gasmi MehdiDirectorJun 17Sale25.012686,703274,442Jun 18 09:45 PM
PATTERSON LEONE DPresidentJun 16Sale24.6813,171325,060110,488Jun 17 05:47 PM
Gasmi MehdiDirectorJun 15Option Exercise4.8010,00048,000284,442Jun 17 05:14 PM
Gasmi MehdiDirectorJun 15Sale21.8610,000218,627274,442Jun 17 05:14 PM
Gasmi MehdiDirectorMay 21Option Exercise4.803,59917,275278,041May 22 06:55 PM
Gasmi MehdiDirectorMay 20Option Exercise4.801,4016,725275,843May 22 06:55 PM
Gasmi MehdiDirectorMay 20Sale20.011,40128,030274,442May 22 06:55 PM
Gasmi MehdiDirectorMay 18Option Exercise4.805,00024,000279,442May 20 07:34 PM
Gasmi MehdiDirectorMay 18Sale18.175,00090,833274,442May 20 07:34 PM
PATTERSON LEONE DCEO, President and DirectorMay 06Option Exercise3.4420,00068,800143,659May 08 06:25 PM
Gasmi MehdiDirectorMay 06Option Exercise4.8025,000120,000299,442May 20 07:34 PM
Gasmi MehdiDirectorMay 06Sale20.0325,000500,668274,442May 20 07:34 PM
PATTERSON LEONE DCEO, President and DirectorMay 06Sale20.0220,000400,400123,659May 08 06:25 PM
Gasmi MehdiDirectorMay 05Option Exercise4.8010,00048,000284,442May 20 07:34 PM
Gasmi MehdiDirectorMay 05Sale16.2610,000162,573274,442May 20 07:34 PM
Scopa James PaulDirectorMay 04Option Exercise6.4823,334151,20453,334May 05 06:44 PM
PATTERSON LEONE DCEO, President and DirectorMar 20Option Exercise3.4424,42484,019162,955Mar 25 05:28 PM
PATTERSON LEONE DCEO, President and DirectorMar 20Sale10.1739,526401,908123,429Mar 25 05:28 PM
PATTERSON LEONE DCEO, President and DirectorMar 17Sale10.024744,749138,531Mar 18 07:33 PM
Gasmi MehdiDirectorFeb 18Option Exercise4.805,00024,000263,979Feb 20 04:51 PM
Gasmi MehdiDirectorFeb 18Sale16.235,00081,156258,979Feb 20 04:51 PM
Scopa James PaulDirectorFeb 14Buy13.7510,000137,50030,000Feb 14 08:58 PM
Gasmi MehdiDirectorFeb 12Option Exercise4.8010,00048,000268,979Feb 14 08:57 PM
Gasmi MehdiDirectorFeb 12Sale15.0710,000150,690258,979Feb 14 08:57 PM